The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma

Ming Yao; Yuan Yuan Shang; Zhi Wei Zhou; Yin Xue Yang; Yin Sheng Wu; Li Feng Guan; Xin Yu Wang; Shu Feng Zhou; Xi Wei

doi:10.7150/jca.16850

The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma

Ming Yao, Yuan Yuan Shang, Zhi Wei Zhou, Yin Xue Yang, Yin Sheng Wu, Li Feng Guan, Xin Yu Wang, Shu Feng Zhou, Xi Wei

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Cutaneous squamous cell carcinoma (cSCC) contributes to one of most common types of skin cancer. Epidermal growth factor receptor (EGFR) activation has been investigated to be associated with the development of cSCC. Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway. We found that lapatinib can inhibit proliferation by enhancing apoptosis of human cSCC cell lines. The cSCC cell cycle distribution could be arrested in G2/M phase after lapatinib treatment. In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells. Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.

Original language	English (US)
Pages (from-to)	220-226
Number of pages	7
Journal	Journal of Cancer
Volume	8
Issue number	2
DOIs	https://doi.org/10.7150/jca.16850
State	Published - 2017
Externally published	Yes

Keywords

Cutaneous squamous cell carcinoma (cSCC)
Epithelial to mesenchymal transition
Lapatinib
Proliferation

ASJC Scopus subject areas

Oncology

Access to Document

10.7150/jca.16850

Cite this

@article{4fb8045cd7a64b40a6b02fc0956c5ef4,

title = "The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma",

abstract = "Cutaneous squamous cell carcinoma (cSCC) contributes to one of most common types of skin cancer. Epidermal growth factor receptor (EGFR) activation has been investigated to be associated with the development of cSCC. Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway. We found that lapatinib can inhibit proliferation by enhancing apoptosis of human cSCC cell lines. The cSCC cell cycle distribution could be arrested in G2/M phase after lapatinib treatment. In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells. Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.",

keywords = "Cutaneous squamous cell carcinoma (cSCC), Epithelial to mesenchymal transition, Lapatinib, Proliferation",

author = "Ming Yao and Shang, {Yuan Yuan} and Zhou, {Zhi Wei} and Yang, {Yin Xue} and Wu, {Yin Sheng} and Guan, {Li Feng} and Wang, {Xin Yu} and Zhou, {Shu Feng} and Xi Wei",

note = "Publisher Copyright: {\textcopyright} Ivyspring International Publisher.",

year = "2017",

doi = "10.7150/jca.16850",

language = "English (US)",

volume = "8",

pages = "220--226",

journal = "Journal of Cancer",

issn = "1837-9664",

publisher = "Ivyspring International Publisher",

number = "2",

}

TY - JOUR

T1 - The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma

AU - Yao, Ming

AU - Shang, Yuan Yuan

AU - Zhou, Zhi Wei

AU - Yang, Yin Xue

AU - Wu, Yin Sheng

AU - Guan, Li Feng

AU - Wang, Xin Yu

AU - Zhou, Shu Feng

AU - Wei, Xi

N1 - Publisher Copyright: © Ivyspring International Publisher.

PY - 2017

Y1 - 2017

N2 - Cutaneous squamous cell carcinoma (cSCC) contributes to one of most common types of skin cancer. Epidermal growth factor receptor (EGFR) activation has been investigated to be associated with the development of cSCC. Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway. We found that lapatinib can inhibit proliferation by enhancing apoptosis of human cSCC cell lines. The cSCC cell cycle distribution could be arrested in G2/M phase after lapatinib treatment. In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells. Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.

AB - Cutaneous squamous cell carcinoma (cSCC) contributes to one of most common types of skin cancer. Epidermal growth factor receptor (EGFR) activation has been investigated to be associated with the development of cSCC. Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway. We found that lapatinib can inhibit proliferation by enhancing apoptosis of human cSCC cell lines. The cSCC cell cycle distribution could be arrested in G2/M phase after lapatinib treatment. In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells. Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.

KW - Cutaneous squamous cell carcinoma (cSCC)

KW - Epithelial to mesenchymal transition

KW - Lapatinib

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=85011036621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011036621&partnerID=8YFLogxK

U2 - 10.7150/jca.16850

DO - 10.7150/jca.16850

M3 - Article

C2 - 28243326

AN - SCOPUS:85011036621

SN - 1837-9664

VL - 8

SP - 220

EP - 226

JO - Journal of Cancer

JF - Journal of Cancer

IS - 2

ER -

The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this